Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) Stock Competitors & Peer Comparison
See AMRX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for AMRX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AMRX | $17.52 | -2.72% | 5.6B | 19.49 | $0.90 | N/A |
| TAK | $17.98 | -0.31% | 57.4B | 12.97 | $1.39 | +3.50% |
| HLN | $10.08 | +0.35% | 44.5B | 18.85 | $0.54 | +1.23% |
| TEVA | $35.97 | -4.40% | 42.4B | 12.43 | $2.93 | N/A |
| ZTS | $76.98 | +2.61% | 32.4B | 11.75 | $6.58 | +2.70% |
| VTRS | $16.38 | -3.02% | 19B | 6.48 | $2.52 | +2.92% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $23.94 | -2.25% | 12B | 22.76 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $12.16 | +0.00% | 10.1B | 19.97 | $0.61 | +0.69% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
AMRX vs TAK Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, TAK has a market cap of 57.4B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while TAK trades at $17.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas TAK's P/E ratio is 12.97. In terms of profitability, AMRX's ROE is -3.27%, compared to TAK's ROE of +0.02%. Regarding short-term risk, AMRX is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check TAK's competition here
Haleon plc (NYSE: HLN)
AMRX vs HLN Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, HLN has a market cap of 44.5B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while HLN trades at $10.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas HLN's P/E ratio is 18.85. In terms of profitability, AMRX's ROE is -3.27%, compared to HLN's ROE of +0.17%. Regarding short-term risk, AMRX is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
AMRX vs TEVA Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, TEVA has a market cap of 42.4B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while TEVA trades at $35.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas TEVA's P/E ratio is 12.43. In terms of profitability, AMRX's ROE is -3.27%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, AMRX is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check TEVA's competition here
Zoetis Inc. (NYSE: ZTS)
AMRX vs ZTS Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, ZTS has a market cap of 32.4B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while ZTS trades at $76.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas ZTS's P/E ratio is 11.75. In terms of profitability, AMRX's ROE is -3.27%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, AMRX is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
AMRX vs VTRS Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, VTRS has a market cap of 19B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while VTRS trades at $16.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas VTRS's P/E ratio is 6.48. In terms of profitability, AMRX's ROE is -3.27%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, AMRX is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
AMRX vs ITCI Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas ITCI's P/E ratio is -180.64. In terms of profitability, AMRX's ROE is -3.27%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, AMRX is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
AMRX vs ELAN Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, ELAN has a market cap of 12B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while ELAN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas ELAN's P/E ratio is 22.76. In terms of profitability, AMRX's ROE is -3.27%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, AMRX is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
AMRX vs CTLT Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas CTLT's P/E ratio is -27.84. In terms of profitability, AMRX's ROE is -3.27%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, AMRX is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
AMRX vs RDY Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, RDY has a market cap of 10.1B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while RDY trades at $12.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas RDY's P/E ratio is 19.97. In terms of profitability, AMRX's ROE is -3.27%, compared to RDY's ROE of +0.09%. Regarding short-term risk, AMRX is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
AMRX vs ALKS Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, ALKS has a market cap of 8B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while ALKS trades at $47.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas ALKS's P/E ratio is 49.91. In terms of profitability, AMRX's ROE is -3.27%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, AMRX is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check ALKS's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
AMRX vs LNTH Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while LNTH trades at $100.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas LNTH's P/E ratio is 16.94. In terms of profitability, AMRX's ROE is -3.27%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, AMRX is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check LNTH's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
AMRX vs INDV Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, INDV has a market cap of 4.4B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while INDV trades at $34.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas INDV's P/E ratio is 9.55. In terms of profitability, AMRX's ROE is -3.27%, compared to INDV's ROE of -2.16%. Regarding short-term risk, AMRX is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check INDV's competition here
Alvotech (NASDAQ: ALVOW)
AMRX vs ALVOW Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, ALVOW has a market cap of 3B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while ALVOW trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas ALVOW's P/E ratio is 47.36. In terms of profitability, AMRX's ROE is -3.27%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, AMRX is less volatile compared to ALVOW. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check ALVOW's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
AMRX vs RGC Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while RGC trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas RGC's P/E ratio is -387.32. In terms of profitability, AMRX's ROE is -3.27%, compared to RGC's ROE of -2.32%. Regarding short-term risk, AMRX is more volatile compared to RGC. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check RGC's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
AMRX vs SUPN Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, SUPN has a market cap of 2.5B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while SUPN trades at $43.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas SUPN's P/E ratio is 14.29. In terms of profitability, AMRX's ROE is -3.27%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, AMRX is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check SUPN's competition here
Bausch Health Companies Inc. (NYSE: BHC)
AMRX vs BHC Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while BHC trades at $6.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas BHC's P/E ratio is 1.61. In terms of profitability, AMRX's ROE is -3.27%, compared to BHC's ROE of +0.89%. Regarding short-term risk, AMRX is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
AMRX vs DCPH Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas DCPH's P/E ratio is -11.58. In terms of profitability, AMRX's ROE is -3.27%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, AMRX is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
AMRX vs HCM Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, HCM has a market cap of 2.2B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while HCM trades at $12.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas HCM's P/E ratio is 4.64. In terms of profitability, AMRX's ROE is -3.27%, compared to HCM's ROE of +0.01%. Regarding short-term risk, AMRX is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
AMRX vs AVDL Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, AMRX's ROE is -3.27%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, AMRX is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check AVDL's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
AMRX vs TRLV Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, TRLV has a market cap of 2B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while TRLV trades at $11.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas TRLV's P/E ratio is -4.80. In terms of profitability, AMRX's ROE is -3.27%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, AMRX is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check TRLV's competition here
Perrigo Company plc (NYSE: PRGO)
AMRX vs PRGO Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, PRGO has a market cap of 2B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while PRGO trades at $14.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas PRGO's P/E ratio is 5.80. In terms of profitability, AMRX's ROE is -3.27%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, AMRX is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check PRGO's competition here
Embecta Corp. (NASDAQ: EMBCV)
AMRX vs EMBCV Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas EMBCV's P/E ratio is N/A. In terms of profitability, AMRX's ROE is -3.27%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, AMRX is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
AMRX vs DVAX Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas DVAX's P/E ratio is -41.89. In terms of profitability, AMRX's ROE is -3.27%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, AMRX is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
AMRX vs ALVO Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, ALVO has a market cap of 1.7B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while ALVO trades at $5.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas ALVO's P/E ratio is -14.56. In terms of profitability, AMRX's ROE is -3.27%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, AMRX is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check ALVO's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
AMRX vs ANIP Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while ANIP trades at $72.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas ANIP's P/E ratio is 8.86. In terms of profitability, AMRX's ROE is -3.27%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, AMRX is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check ANIP's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
AMRX vs ETON Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while ETON trades at $58.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas ETON's P/E ratio is 129.96. In terms of profitability, AMRX's ROE is -3.27%, compared to ETON's ROE of +0.40%. Regarding short-term risk, AMRX is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check ETON's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
AMRX vs TARO Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas TARO's P/E ratio is 30.05. In terms of profitability, AMRX's ROE is -3.27%, compared to TARO's ROE of +0.03%. Regarding short-term risk, AMRX is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
AMRX vs PAHC Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, PAHC has a market cap of 1.5B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while PAHC trades at $37.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas PAHC's P/E ratio is 12.86. In terms of profitability, AMRX's ROE is -3.27%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, AMRX is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check PAHC's competition here
Harrow Health, Inc. (NASDAQ: HROW)
AMRX vs HROW Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while HROW trades at $36.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas HROW's P/E ratio is -37.65. In terms of profitability, AMRX's ROE is -3.27%, compared to HROW's ROE of -1.04%. Regarding short-term risk, AMRX is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check HROW's competition here
Cronos Group Inc. (NASDAQ: CRON)
AMRX vs CRON Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while CRON trades at $3.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas CRON's P/E ratio is 32.10. In terms of profitability, AMRX's ROE is -3.27%, compared to CRON's ROE of +0.06%. Regarding short-term risk, AMRX is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check CRON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
AMRX vs PCRX Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while PCRX trades at $25.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas PCRX's P/E ratio is 9.91. In terms of profitability, AMRX's ROE is -3.27%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, AMRX is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check PCRX's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
AMRX vs AMPH Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, AMPH has a market cap of 970.5M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while AMPH trades at $22.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas AMPH's P/E ratio is 7.51. In terms of profitability, AMRX's ROE is -3.27%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, AMRX is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check AMPH's competition here
PetIQ, Inc. (NASDAQ: PETQ)
AMRX vs PETQ Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas PETQ's P/E ratio is 83.73. In terms of profitability, AMRX's ROE is -3.27%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, AMRX is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
AMRX vs COLL Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, COLL has a market cap of 822.2M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while COLL trades at $24.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas COLL's P/E ratio is 3.18. In terms of profitability, AMRX's ROE is -3.27%, compared to COLL's ROE of +0.16%. Regarding short-term risk, AMRX is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check COLL's competition here
Glass House Brands Inc (NYSE: GLAS)
AMRX vs GLAS Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, GLAS has a market cap of 768.1M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while GLAS trades at $9.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas GLAS's P/E ratio is -17.73. In terms of profitability, AMRX's ROE is -3.27%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, AMRX is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check GLAS's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
AMRX vs IRWD Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, IRWD has a market cap of 698M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while IRWD trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas IRWD's P/E ratio is 5.44. In terms of profitability, AMRX's ROE is -3.27%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, AMRX is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check IRWD's competition here
Evotec SE (NASDAQ: EVO)
AMRX vs EVO Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, EVO has a market cap of 678.5M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while EVO trades at $1.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas EVO's P/E ratio is -2.70. In terms of profitability, AMRX's ROE is -3.27%, compared to EVO's ROE of -0.27%. Regarding short-term risk, AMRX is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check EVO's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
AMRX vs AQST Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, AQST has a market cap of 629.8M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while AQST trades at $5.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas AQST's P/E ratio is -7.72. In terms of profitability, AMRX's ROE is -3.27%, compared to AQST's ROE of +2.44%. Regarding short-term risk, AMRX is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check AQST's competition here
Evolus, Inc. (NASDAQ: EOLS)
AMRX vs EOLS Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, EOLS has a market cap of 584.8M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while EOLS trades at $9.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas EOLS's P/E ratio is -28.12. In terms of profitability, AMRX's ROE is -3.27%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, AMRX is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check EOLS's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
AMRX vs BDSI Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas BDSI's P/E ratio is 6.82. In terms of profitability, AMRX's ROE is -3.27%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, AMRX is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check BDSI's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
AMRX vs TLRY Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, TLRY has a market cap of 513.3M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while TLRY trades at $4.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas TLRY's P/E ratio is -4.23. In terms of profitability, AMRX's ROE is -3.27%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, AMRX is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check TLRY's competition here
Kamada Ltd. (NASDAQ: KMDA)
AMRX vs KMDA Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, KMDA has a market cap of 476.6M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while KMDA trades at $8.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas KMDA's P/E ratio is 21.74. In terms of profitability, AMRX's ROE is -3.27%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, AMRX is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
AMRX vs CGC Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, CGC has a market cap of 421.9M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while CGC trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas CGC's P/E ratio is -0.60. In terms of profitability, AMRX's ROE is -3.27%, compared to CGC's ROE of -0.33%. Regarding short-term risk, AMRX is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
AMRX vs TKNO Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, TKNO has a market cap of 381.7M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while TKNO trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas TKNO's P/E ratio is -22.97. In terms of profitability, AMRX's ROE is -3.27%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, AMRX is more volatile compared to TKNO. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check TKNO's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
AMRX vs EBS Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, EBS has a market cap of 305.2M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while EBS trades at $6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas EBS's P/E ratio is 4.11. In terms of profitability, AMRX's ROE is -3.27%, compared to EBS's ROE of -0.36%. Regarding short-term risk, AMRX is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
AMRX vs ALIM Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas ALIM's P/E ratio is 5.28. In terms of profitability, AMRX's ROE is -3.27%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, AMRX is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
AMRX vs LNDC Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas LNDC's P/E ratio is -4.04. In terms of profitability, AMRX's ROE is -3.27%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, AMRX is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
AMRX vs ACB Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, ACB has a market cap of 248.4M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while ACB trades at $4.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas ACB's P/E ratio is -8.19. In terms of profitability, AMRX's ROE is -3.27%, compared to ACB's ROE of -0.21%. Regarding short-term risk, AMRX is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check ACB's competition here
Shineco, Inc. (NASDAQ: TYHT)
AMRX vs TYHT Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas TYHT's P/E ratio is -1.61. In terms of profitability, AMRX's ROE is -3.27%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, AMRX is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check TYHT's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
AMRX vs ORGO Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, ORGO has a market cap of 223.9M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while ORGO trades at $1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas ORGO's P/E ratio is 58.00. In terms of profitability, AMRX's ROE is -3.27%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, AMRX is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check ORGO's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
AMRX vs CRDL Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, CRDL has a market cap of 223.6M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while CRDL trades at $1.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas CRDL's P/E ratio is -7.73. In terms of profitability, AMRX's ROE is -3.27%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, AMRX is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check CRDL's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
AMRX vs SIGA Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, SIGA has a market cap of 219.5M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while SIGA trades at $3.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas SIGA's P/E ratio is 11.33. In terms of profitability, AMRX's ROE is -3.27%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, AMRX is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check SIGA's competition here
Journey Medical Corporation (NASDAQ: DERM)
AMRX vs DERM Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, DERM has a market cap of 205.6M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while DERM trades at $7.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas DERM's P/E ratio is -20.19. In terms of profitability, AMRX's ROE is -3.27%, compared to DERM's ROE of -0.20%. Regarding short-term risk, AMRX is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check DERM's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
AMRX vs REPH Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas REPH's P/E ratio is -8.04. In terms of profitability, AMRX's ROE is -3.27%, compared to REPH's ROE of -0.22%. Regarding short-term risk, AMRX is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check REPH's competition here
Organigram Global Inc. (NASDAQ: OGI)
AMRX vs OGI Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, OGI has a market cap of 171M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while OGI trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas OGI's P/E ratio is 2.73. In terms of profitability, AMRX's ROE is -3.27%, compared to OGI's ROE of +0.21%. Regarding short-term risk, AMRX is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
AMRX vs LFCR Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, LFCR has a market cap of 170.3M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while LFCR trades at $4.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas LFCR's P/E ratio is -4.24. In terms of profitability, AMRX's ROE is -3.27%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, AMRX is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check LFCR's competition here
Theratechnologies Inc. (NASDAQ: THTX)
AMRX vs THTX Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas THTX's P/E ratio is -28.83. In terms of profitability, AMRX's ROE is -3.27%, compared to THTX's ROE of +0.17%. Regarding short-term risk, AMRX is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
AMRX vs ASRT Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas ASRT's P/E ratio is -7.10. In terms of profitability, AMRX's ROE is -3.27%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, AMRX is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check ASRT's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
AMRX vs CPIX Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, CPIX has a market cap of 126.8M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while CPIX trades at $7.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas CPIX's P/E ratio is -21.15. In terms of profitability, AMRX's ROE is -3.27%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, AMRX is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check CPIX's competition here
BGM Group Ltd. (NASDAQ: BGM)
AMRX vs BGM Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, BGM has a market cap of 122.1M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while BGM trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas BGM's P/E ratio is -1.11. In terms of profitability, AMRX's ROE is -3.27%, compared to BGM's ROE of -0.07%. Regarding short-term risk, AMRX is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check BGM's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
AMRX vs SCTL Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas SCTL's P/E ratio is -7.86. In terms of profitability, AMRX's ROE is -3.27%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, AMRX is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check SCTL's competition here
Procaps Group S.A. (NASDAQ: PROC)
AMRX vs PROC Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas PROC's P/E ratio is 1.53. In terms of profitability, AMRX's ROE is -3.27%, compared to PROC's ROE of -2.22%. Regarding short-term risk, AMRX is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
AMRX vs OPTN Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas OPTN's P/E ratio is -4.42. In terms of profitability, AMRX's ROE is -3.27%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, AMRX is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
AMRX vs ZOM Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas ZOM's P/E ratio is -1.62. In terms of profitability, AMRX's ROE is -3.27%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, AMRX is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
AMRX vs GRVI Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas GRVI's P/E ratio is 26.05. In terms of profitability, AMRX's ROE is -3.27%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, AMRX is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
AMRX vs ZYBT Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, ZYBT has a market cap of 82M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while ZYBT trades at $1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas ZYBT's P/E ratio is -7.86. In terms of profitability, AMRX's ROE is -3.27%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, AMRX is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check ZYBT's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
AMRX vs ZYNE Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, AMRX's ROE is -3.27%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, AMRX is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check ZYNE's competition here
InterCure Ltd. (NASDAQ: INCR)
AMRX vs INCR Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, INCR has a market cap of 68.5M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while INCR trades at $5.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas INCR's P/E ratio is -13.34. In terms of profitability, AMRX's ROE is -3.27%, compared to INCR's ROE of -0.09%. Regarding short-term risk, AMRX is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check INCR's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
AMRX vs SSIC Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas SSIC's P/E ratio is 11.93. In terms of profitability, AMRX's ROE is -3.27%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, AMRX is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check SSIC's competition here
Talphera, Inc. (NASDAQ: TLPH)
AMRX vs TLPH Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, TLPH has a market cap of 62.3M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while TLPH trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas TLPH's P/E ratio is -3.87. In terms of profitability, AMRX's ROE is -3.27%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, AMRX is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check TLPH's competition here
The Valens Company Inc. (NASDAQ: VLNS)
AMRX vs VLNS Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas VLNS's P/E ratio is -1.03. In terms of profitability, AMRX's ROE is -3.27%, compared to VLNS's ROE of N/A. Regarding short-term risk, AMRX is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
AMRX vs DRRX Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas DRRX's P/E ratio is -4.44. In terms of profitability, AMRX's ROE is -3.27%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, AMRX is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check DRRX's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
AMRX vs JUPW Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas JUPW's P/E ratio is -2.41. In terms of profitability, AMRX's ROE is -3.27%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, AMRX is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
AMRX vs QLI Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas QLI's P/E ratio is -4.92. In terms of profitability, AMRX's ROE is -3.27%, compared to QLI's ROE of -0.16%. Regarding short-term risk, AMRX is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check QLI's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
AMRX vs CPHI Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, CPHI has a market cap of 36.6M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while CPHI trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas CPHI's P/E ratio is -2.10. In terms of profitability, AMRX's ROE is -3.27%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, AMRX is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check CPHI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
AMRX vs RMTI Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, RMTI has a market cap of 32.2M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while RMTI trades at $8.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas RMTI's P/E ratio is -6.10. In terms of profitability, AMRX's ROE is -3.27%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, AMRX is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
AMRX vs HEXO Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas HEXO's P/E ratio is -0.26. In terms of profitability, AMRX's ROE is -3.27%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, AMRX is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check HEXO's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
AMRX vs TXMD Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, TXMD has a market cap of 25.7M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while TXMD trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas TXMD's P/E ratio is 113.09. In terms of profitability, AMRX's ROE is -3.27%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, AMRX is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check TXMD's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
AMRX vs AYTU Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, AYTU has a market cap of 24.1M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while AYTU trades at $2.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas AYTU's P/E ratio is -1.17. In terms of profitability, AMRX's ROE is -3.27%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, AMRX is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check AYTU's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
AMRX vs CYTH Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas CYTH's P/E ratio is -0.80. In terms of profitability, AMRX's ROE is -3.27%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, AMRX is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
AMRX vs EVOK Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas EVOK's P/E ratio is -7.97. In terms of profitability, AMRX's ROE is -3.27%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, AMRX is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
AMRX vs OPTH Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, OPTH has a market cap of 15.9M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while OPTH trades at $4.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas OPTH's P/E ratio is -18.08. In terms of profitability, AMRX's ROE is -3.27%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, AMRX is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
AMRX vs ACRX Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas ACRX's P/E ratio is -0.31. In terms of profitability, AMRX's ROE is -3.27%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, AMRX is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
AMRX vs CABR Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, CABR has a market cap of 12.6M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while CABR trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas CABR's P/E ratio is -2.48. In terms of profitability, AMRX's ROE is -3.27%, compared to CABR's ROE of -3.28%. Regarding short-term risk, AMRX is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
AMRX vs AGRX Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas AGRX's P/E ratio is -0.89. In terms of profitability, AMRX's ROE is -3.27%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, AMRX is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
AMRX vs NLTX Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas NLTX's P/E ratio is -0.28. In terms of profitability, AMRX's ROE is -3.27%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, AMRX is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
AMRX vs LCI Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas LCI's P/E ratio is -0.04. In terms of profitability, AMRX's ROE is -3.27%, compared to LCI's ROE of +1.66%. Regarding short-term risk, AMRX is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
AMRX vs ADMP Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas ADMP's P/E ratio is -0.08. In terms of profitability, AMRX's ROE is -3.27%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, AMRX is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
AMRX vs YCBD Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, YCBD has a market cap of 5.3M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while YCBD trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas YCBD's P/E ratio is -1.25. In terms of profitability, AMRX's ROE is -3.27%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, AMRX is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
AMRX vs GELS Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, GELS has a market cap of 5.1M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while GELS trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas GELS's P/E ratio is -1.11. In terms of profitability, AMRX's ROE is -3.27%, compared to GELS's ROE of -0.25%. Regarding short-term risk, AMRX is more volatile compared to GELS. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
AMRX vs MNK Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas MNK's P/E ratio is -0.44. In terms of profitability, AMRX's ROE is -3.27%, compared to MNK's ROE of -0.36%. Regarding short-term risk, AMRX is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
AMRX vs FLGC Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas FLGC's P/E ratio is -0.19. In terms of profitability, AMRX's ROE is -3.27%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, AMRX is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
AMRX vs UPC Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, UPC has a market cap of 3.1M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while UPC trades at $4.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas UPC's P/E ratio is -0.62. In terms of profitability, AMRX's ROE is -3.27%, compared to UPC's ROE of -0.03%. Regarding short-term risk, AMRX is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
AMRX vs SBFM Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, SBFM has a market cap of 2.7M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while SBFM trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas SBFM's P/E ratio is -0.19. In terms of profitability, AMRX's ROE is -3.27%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, AMRX is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
AMRX vs PLXP Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas PLXP's P/E ratio is -0.22. In terms of profitability, AMRX's ROE is -3.27%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, AMRX is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
AMRX vs ATNX Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas ATNX's P/E ratio is -0.02. In terms of profitability, AMRX's ROE is -3.27%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, AMRX is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for AMRX.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
AMRX vs SNOA Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, SNOA has a market cap of 2.2M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while SNOA trades at $1.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas SNOA's P/E ratio is -1.11. In terms of profitability, AMRX's ROE is -3.27%, compared to SNOA's ROE of -0.46%. Regarding short-term risk, AMRX is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check SNOA's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
AMRX vs SHPH Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, SHPH has a market cap of 2.1M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while SHPH trades at $3.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas SHPH's P/E ratio is -0.17. In terms of profitability, AMRX's ROE is -3.27%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, AMRX is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check SHPH's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
AMRX vs RDHL Comparison September 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRX stands at 5.6B. In comparison, RDHL has a market cap of 2.1M. Regarding current trading prices, AMRX is priced at $17.52 on the NASDAQ, while RDHL trades at $1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRX currently has a P/E ratio of 19.49, whereas RDHL's P/E ratio is 0.13. In terms of profitability, AMRX's ROE is -3.27%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, AMRX is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for AMRX.Check RDHL's competition here